Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: Diabetes-Patienten-Verlaufsdokumentation (DPV) registry study
An erratum to this article was published (Diabetes Obes Metab, Dec 2026 ↗)
Authors' conclusion
Despite variations in patient profiles, Gla-300 is widely used across all CKD stages, particularly in advanced stages with a low rate of severe hypoglycemia, suggesting its safe administration in CKD patients.
Study context
- Population
- T2D patients with chronic kidney disease (CKD), routine data from the prospective DPV registry, across CKD stages
- Participants
- 21,359 patients
- Exposure
- Gla-300 vs no insulin
- Gla-300n = 1,786
- Non-insulinn = 19,568reference
- Outcome
- Patient characteristics, Gla-300 vs non-insulin
Methodological detailsregistry-based (DPV)
- Registry-based (DPV)
Main finding
As reported in the abstract
Age at T2D onset (median), Gla-300 vs non-insulin
55.1 vs. 62.3 years
Diabetes duration, Gla-300 vs non-insulin
17.3 vs. 11.3 years
Body weight, Gla-300 vs non-insulin
91.3 vs. 83.9 kg
HbA1c, Gla-300 vs non-insulin
7.3% vs. 6.7%
Observational data: associations, not effects.
Further findings
Gla-300 use by CKD stage
- Median Gla-300 dose, CKD stage 1 vs 4
- 44 vs. 55 units
- Baseline HbA1c, CKD stage 1 vs 4
- 7.2% vs. 7.4%
- Stage 5 CKD: HbA1c
- 6.9%
- Stage 5 CKD: body weight
- 90 kg
- Stage 5 CKD: Gla-300 usage
- 50 units
- Metformin, SGLT-2 inhibitors and GLP-1 RA common concomitant drugs with diminished usage in advanced CKD; Gla-300 common at all stages
Safety
Severe hypoglycemia
- Low rates; slight increase with decreasing eGFR
- 0.01%/PY vs. 0.04%/PY
Original publication
Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study. Diabetes Obes Metab. Published 19 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →